Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: March 26, 2023

Triclabendazole - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What are the generic sources for triclabendazole and what is the scope of patent protection?

Triclabendazole is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for triclabendazole. One supplier is listed for this compound.

Summary for triclabendazole
US Patents:0
Drug Master File Entries: 1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 122
Clinical Trials: 2
Patent Applications: 2,882
What excipients (inactive ingredients) are in triclabendazole?triclabendazole excipients list
DailyMed Link:triclabendazole at DailyMed
Recent Clinical Trials for triclabendazole

Identify potential brand extensions & 505(b)(2) entrants

Novartis PharmaceuticalsPhase 4
University of Colorado, Denver

See all triclabendazole clinical trials

US Patents and Regulatory Information for triclabendazole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis EGATEN triclabendazole TABLET;ORAL 208711-001 Feb 13, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis EGATEN triclabendazole TABLET;ORAL 208711-001 Feb 13, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.